Skip to Content

Available Cancer Clinical Trials

Explore your potential options for participating in a clinical trial through the Rush Copley Cancer Care Center. Some of the following available cancer clinical trials may require you to participate in other activities in addition to getting treatment. These activities may include completing logs, answering questionnaires and making more frequent doctor visits than non-participants. To give the trial its best chance of success, follow all your medical team’s instructions during the study period.

Clinical trials may have guidelines that detail certain qualities researchers are looking for in participants. These qualities may include age, type and stage of cancer, sex and previous treatments you’ve attempted. Talk to your doctor to determine if you meet the criteria and are eligible to participate.

Brain Cancer

Alliance A071102: Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Alliance A221101: Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma

Breast Cancer

Alliance A011202: Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

Alliance A011203: Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients with Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

BCCR: Breast Cancer Collaborative Registry

ECOG-ACRIN EAY131: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

ECOG E1Z11: Anastrozole in Treating Aromatase Inhibitor Musculoskeletal Symptoms in Female Patients with Stage I-III Breast Cancer

ECOG-ACRIN E2112: Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That Is Locally Advanced or Metastatic

NRG BR002: Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer

NRG BR003: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel with or without Carboplatin in Treating Patients with Triple-Negative Breast Cancer

NSABP B-51: Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

NSABP B-52: Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

SWOG S1207: Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Colorectal Cancer

CALGB 80702: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

ECOG E7208: Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy (Temporarily Unavailable)

SWOG S1406: Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

Gynecologic Cancer

Endometrial (Uterine)

NRG GOG 0286B: Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

Ovarian

NRG GOG 281: Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Uterine

GOG 0277: Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery

Other

GOG 275: Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia

Head & Neck Cancer

NRG HN001: Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

RTOG 0920: Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

RTOG 1216: Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer

Leukemia

Alliance A041202: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

ECOG-ACRIN E1912: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Liver Cancer

CALGB 80802: Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

RTOG 1112: Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

Lung Cancer

Non-small cell

Alliance A081105: Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Alliance A151216: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery

NRG LU001: Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

ACCRU RC1126: Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations

SWOG S1400: Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer

Small cell

ECOG-ACRIN E2511: Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-Small Cell Lung Cancer

Lymphoma

Non-Hodgkin’s

ECOG-ACRIN E1412: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

ECOG E2408: Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Melanoma

ECOG E3611: Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

ECOG-ACRIN E3612: Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Multiple Myeloma

ECOG-ACRIN E1A11: Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Pancreatic Cancer

RTOG 0848: Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

Prostate Cancer

Alliance A031201: Enzalutamide With or Without Abiraterone Acetate and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

RTOG 0924: Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

SWOG S1216: Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

Renal Cell Carcinoma (Kidney Cancer)

ECOG E2810: Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

SWOG S0931: Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

Sarcoma

Alliance A091202: Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients With Previously Treated, Unresectable Myxoid Liposarcoma

Waterford Place

Cancer Support at Waterford Place

Waterford Place Cancer Resource Center, located adjacent to Rush Copley’s Aurora campus at 1310 Waterford Drive, provides services and support to anyone impacted by a cancer diagnosis. Waterford Place is a warm, welcoming environment where participants can connect with support services including mind-body classes, expressive therapies and informational programs along with a salon featuring an American Cancer Society® wig boutique. Programming focuses on the practical, from what to expect from treatment to how to balance practical concerns such as finances, working, health insurance as well as the emotional side of the disease. Regular lectures from clinical specialists and other health professionals help keep you informed on the latest research and treatment options, and on topics such as how to help caregivers and maintain relationships.